What's New

News

2017/09/28
Updated information of CSR
2017/08/31
Nippon Kayaku announces the final data analysis of a global phase 3 study of NK105, a novel macromolecular micelle encapsulating an anticancer drug, will be presented at the ESMO 2017 Congress
2017/04/26
Agreement on major articles of contract for collaboration for CT-P10, in Japan
2017/04/11
Submission of Application for Marketing Approval of CT-P6 Trastuzumab Biosimilar Monoclonal Antibody in Japan
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR